Author:
Zhao Xuewei,Feng Zhangying,Wang Guanqi,Pang Haiying,Wang Mingxia
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference42 articles.
1. Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009
2. First-in-human evaluation of CO-1686, an irreversible, highly, selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M);Soria;J Thorac Oncol,2014
3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013
4. What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?;Ochi;Transl Cancer Res,2017
5. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC;Ou;Ann Oncol,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献